Clinical Trials
Why take part in a clinical trial?
RESEARCH IS THE KEY TO DESTROY T1D
Why Volunteer?
- You could get access to new therapies before they are available on the market
- You’ll learn more about your own T1D and how to manage it
- You’ll help to advance research progress
- You’ll contribute to making new therapies accessible to people with T1D
- You could help find a cure for the millions of people worldwide living with T1D

LEARN MORE
How Does a Clinical Trial Work?
Find a Clinical Trial
The closed loop therapy study will trial the world’s most advanced commercial automated insulin delivery system (MiniMed™ 780G) in youth with broad ethnic backgrounds. The study will identify if AHCL is an appropriate and safe therapy for youth struggling with diabetes. While better control of glucose levels is a key outcome for this trial, other features such as burden reduction, improved quality of life and treatment satisfaction will also be explored.
This world-first longitudinal study will be an important step towards integrating AHCL technology into regular diabetes care for youth, with the expectation that it will reduce daily diabetes management burden and improve short-term and long-term health outcomes in this high risk group.
For more information, contact Associate Professor Ben Wheeler.
Key Requirements- Age: 13 – 25 years
- Diagnosed with Type1 Diabetes
- History of HbA1c levels ≥ 69 mmol/mol
- Using traditional injection therapy
New technology, like the intermittently scanned continuous glucose monitoring (isCGM; FreeSyle® Libre 2) could improve glucose monitoring and diabetes control for children, as it discreetly provides accurate and up-to-date glucose information.
The Flash-2 study aims to investigate the isCGM device using a randomised controlled trial in 100 young NZ children (aged 4-13 years). Given children’s propensity for new technology, the ease of being able to scan (even through clothing), and the reduction in finger pricking, isCGM may provide a great opportunity to engage children in their diabetes care and help them and their families to improve self-management behaviours.
This study continues the research group’s broad aim of helping to provide healthier, more equitable and cost-effective diabetes care to children and their families.
Key Requirements
- Age: 4 – 13 years
- Diagnosed with Type1 Diabetes
- Parental permission
To find out if your child is eligible for this study please contact Associate Professor Ben Wheeler.